By Josh White
Date: Wednesday 25 Sep 2024
(Sharecast News) - Shield Therapeutics announced promising results from its phase three paediatric clinical trial for 'Accrufer' and 'Ferracru', or ferric maltol, in treating iron deficiency anaemia (IDA) in children on Wednesday.
The AIM-traded firm said the trial showed significant efficacy, safety, and tolerability of the oral liquid suspension, paving the...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news